News tagged ‘OvarianCancer’ clear
- Dana-Farber researchers have demonstrated a molecular strategy that they say could make a much larger variety of tumors treatable with PARP inhibitors, a promising new class of cancer drugs.
Tags: BreastCancer, OvarianCancer, GynecologicCancers
- Significant improvement with the use of a combination drug therapy for recurrent ovarian cancer was reported at the annual meeting of the American Society of Clinical Oncology (ASCO) meeting in Chicago today. This is the first ovarian cancer study to use a combination of drugs that could be taken orally.
Tags: OvarianCancer, TargetedTherapy
- Dana-Farber/Brigham and Women's Cancer Center has joined forces with the
Massachusetts Chapter of the National Ovarian Cancer Coalition and The
M. Patricia Cronin Foundation to launch a month-long campaign to promote
ovarian cancer awareness.
- Ursula Matulonis, MD, the director of the Gynecological Cancer Treatment Center in the Susan F. Smith Center for Women’s Cancers at Dana-Farber receives a $900,000 grant from the Ovarian Cancer Research Foundation (OCRF) to test new combinations of targeted drugs against the disease.
Tags: Grants, OvarianCancer, GynecologicCancers
- Dana-Farber's Alan D'Andrea, MD, has been selected to lead a Stand Up To Cancer Dream Team devoted to ovarian cancer research. The team will focus on DNA repair therapies for ovarian cancer.
Tags: OvarianCancer, TranslationalResearch
- A widely used diabetes drug dramatically boosted the potency of
platinum-based cancer drugs when administered together to a variety of
cancer cell lines and to mice with tumors, scientists from Dana-Farber
Tags: LungCancer, OvarianCancer
- Scientists from Brigham and Women's Hospital and Dana-Farber Cancer Institute and their colleagues have found a genetic marker that predicts which aggressive "triple negative" breast cancers and certain ovarian cancers will likely respond to platinum-based chemotherapies.
Tags: BasicResearch, BreastCancer, Genomics, OvarianCancer, GynecologicCancers
- Researchers from the Susan F. Smith Center for Women’s Cancers at Dana-Farber report that for some women with recurrent ovarian cancer, a new drug combination has been found to stall the progression of the disease.
Tags: OvarianCancer, GynecologicCancers